Insider Selling: Atara Biotherapeutics, Inc. (ATRA) CEO Sells $62,700.00 in Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 4,400 shares of the company’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $14.25, for a total transaction of $62,700.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of Atara Biotherapeutics, Inc. (NASDAQ ATRA) opened at $14.60 on Monday. Atara Biotherapeutics, Inc. has a twelve month low of $11.80 and a twelve month high of $23.00.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Thursday, November 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.97) by ($0.05). sell-side analysts anticipate that Atara Biotherapeutics, Inc. will post -4 earnings per share for the current year.

Several analysts recently issued reports on ATRA shares. Canaccord Genuity reaffirmed a “buy” rating and issued a $47.00 price target on shares of Atara Biotherapeutics in a report on Monday, September 11th. ValuEngine raised shares of Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Zacks Investment Research cut shares of Atara Biotherapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 28th. Jefferies Group reaffirmed a “buy” rating and issued a $30.00 price target on shares of Atara Biotherapeutics in a report on Thursday, August 31st. Finally, BidaskClub cut shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. Three analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $24.40.

Several large investors have recently modified their holdings of the business. Dimensional Fund Advisors LP raised its holdings in shares of Atara Biotherapeutics by 2.9% during the second quarter. Dimensional Fund Advisors LP now owns 21,718 shares of the biotechnology company’s stock worth $304,000 after purchasing an additional 610 shares during the period. Teachers Advisors LLC raised its holdings in shares of Atara Biotherapeutics by 2.4% during the second quarter. Teachers Advisors LLC now owns 47,156 shares of the biotechnology company’s stock worth $660,000 after purchasing an additional 1,110 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of Atara Biotherapeutics by 7.2% during the second quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock worth $285,000 after purchasing an additional 1,369 shares during the period. Alps Advisors Inc. raised its holdings in shares of Atara Biotherapeutics by 5.8% during the second quarter. Alps Advisors Inc. now owns 26,274 shares of the biotechnology company’s stock worth $368,000 after purchasing an additional 1,445 shares during the period. Finally, Voya Investment Management LLC raised its holdings in shares of Atara Biotherapeutics by 16.2% during the second quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 1,651 shares during the period. 85.61% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Insider Selling: Atara Biotherapeutics, Inc. (ATRA) CEO Sells $62,700.00 in Stock” was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.com-unik.info/2017/12/04/insider-selling-atara-biotherapeutics-inc-atra-ceo-sells-62700-00-in-stock.html.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

What are top analysts saying about Atara Biotherapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Atara Biotherapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit